Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis

被引：0
|
作者：
Bernard Combe
Robin Besuyen
Antonio Gómez-Centeno
Tsukasa Matsubara
Juan José Sancho Jimenez
Zhaoyu Yin
Maya H. Buch
机构：
[1] University of Montpellier,NIHR Manchester Biomedical Research Centre
[2] Galapagos BV,undefined
[3] Hospital Universitari Parc Tauli,undefined
[4] Sabadell,undefined
[5] Matsubara Mayflower Hospital,undefined
[6] Galapagos,undefined
[7] Gilead Sciences,undefined
[8] Inc.,undefined
[9] University of Manchester,undefined
来源：
Rheumatology and Therapy | 2023年 / 10卷
关键词：
Adverse effects; Disease-modifying antirheumatic drug; Filgotinib; Outcomes; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Clinical trials in rheumatoid arthritis recruit too few patients from diverse ethnic backgrounds to be able to identify differences in treatment outcomes. In adults with moderate-to-severe active rheumatoid arthritis who do not tolerate or have responded poorly to other advanced treatments, the Janus kinase inhibitor filgotinib can be used alone or in combination with the immunosuppressant methotrexate. Using data from 4695 patients with rheumatoid arthritis from five previous clinical trials and two ongoing trial extensions, this paper examined the efficacy and safety of filgotinib in patients with rheumatoid arthritis across geographic locations worldwide.
引用
收藏
页码：35 / 51
页数：16
相关论文
共 50 条
  • [21] Filgotinib for the treatment of rheumatoid arthritis
    Taylor, Peter C.
    Azeez, Maha Abdul
    Kiriakidis, Serafim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (10) : 1181 - 1187
  • [22] Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65)
    Benucci, Maurizio
    Bardelli, Marco
    Cazzato, Massimiliano
    Bartoli, Francesca
    Damiani, Arianna
    Li Gobbi, Francesca
    Bandinelli, Francesca
    Panaccione, Anna
    Di Cato, Luca
    Niccoli, Laura
    Frediani, Bruno
    Mosca, Marta
    Guiducci, Serena
    Cantini, Fabrizio
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (07):
  • [23] Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH 1 Primary Outcome Results
    Keystone, Edward
    Combe, Bernard
    Kivitz, Alan
    Tanaka, Yoshiya
    van der Heijde, Desiree
    Matzkies, Franziska
    Bartok, Beatrix
    Ye, Lie
    Guo, Ying
    Tasset, Chantal
    Sundy, John
    Mozaffarian, Neelufar
    Landewe, Robert
    Bae, Sang-Cheol
    Nash, Peter
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1108 - 1108
  • [24] Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
    Lee, Y. H.
    Song, G. G.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (06): : 590 - 603
  • [25] Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
    Aletaha, Daniel
    Westhovens, Rene
    Gaujoux-Viala, Cecile
    Adami, Giovanni
    Matsumoto, Alan
    Bird, Paul
    Messina, Osvaldo Daniel
    Buch, Maya H.
    Bartok, Beatrix
    Yin, Zhaoyu
    Guo, Ying
    Hendrikx, Thijs
    Burmester, Gerd R.
    RMD OPEN, 2021, 7 (02):
  • [26] Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naive to Methotrexate Therapy: FINCH 3 Primary Outcome Results
    Haaland, Derek
    van der Heijde, Desiree
    Westhovens, Rene
    Rigby, William
    Ching, Daniel
    Bartok, Beatrix
    Matzkies, Franziska
    Yin, Zhaoyu
    Guo, Ying
    Paulino, Marcelo
    Tasset, Chantal
    Sundy, John
    Mozaffarian, Neelufar
    Messina, Osvaldo
    Landewe, Robert
    Atsumi, Tatsuya
    Burmester, Gerd
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1084 - 1085
  • [27] Evaluating filgotinib for the treatment of rheumatoid arthritis
    Richez, Christophe
    Truchetet, Marie-Elise
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (18) : 2435 - 2444
  • [28] EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS
    Combe, Bernard
    Kivitz, Alan
    Tanaka, Yoshiya
    van der Heijde, Desiree
    Matzkies, Franziska
    Bartok, Beatrix
    Ye, Lei
    Guo, Ying
    Tasset, Chantal
    Sundy, John
    Mozaffarian, Neelufar
    Landewe, Robert B. M.
    Bae, Sang-Cheol
    Keystone, Edward C.
    Nash, Peter
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 77 - 78
  • [29] EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS
    Combe, B.
    Kivitz, A.
    Tanaka, Y.
    Van der Heijde, D.
    Simon-Campos, J. A.
    Baraf, H. S. B.
    Kumar, U.
    Matzkies, F.
    Bartok, B.
    Ye, L.
    Guo, Y.
    Tasset, C.
    Sundy, J.
    Jahreis, A.
    Mozaffarian, N.
    Landewe, R. B. M.
    Bae, S. C.
    Keystone, E.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 316 - 317
  • [30] Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience
    La Barbera, L.
    Rizzo, C.
    Camarda, F.
    Atzeni, F.
    Miceli, G.
    Colella, A. B. Molica
    Franchina, V.
    Giardina, A.
    Corrao, S.
    Provenzano, G.
    Bursi, R.
    Foti, R.
    Dal Bosco, Y.
    Debilio, C.
    Luppino, F.
    Colaci, M.
    Aprile, M. L.
    Bentivegna, M.
    Cassara, E.
    Lo Gullo, A.
    De Andres, M. I.
    Guggino, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (05) : 991 - 998
12345